Clinical Evaluation of Vaginal Contraceptive Cream of Sapindus mukorossi, CONSAP: A Pilot Study

Authors

  • Vivek Vidyadhar Bhosale Division of Clinical and Experimental Medicine, CSIR-Central Drug Research Institute, Communication No. 9151, Lucknow-226031, U.P., India
  • Ashim Ghatak Division of Clinical and Experimental Medicine, CSIR-Central Drug Research Institute, Communication No. 9151, Lucknow-226031, U.P., India

DOI:

https://doi.org/10.37591/tdd.v2i3.282

Abstract

Sapindus mukorossi also known as reetha is well known herb in ancient Ayurveda. The fruits of this herb contain saponins which showed excellent spermicidal activity in vitro and in vivo animal experiments. The formulation in the form of cream was prepared for human application. The safety and tolerability pilot clinical study was organized. The aim of the present study was to evaluate the contraceptive safety and efficacy of 2.5% cream when used intravaginally before coitus. The women volunteers were instructed to use 2.5% CONSAP cream in loading dose of 3 gm, 5–7 min before coitus and present herself for post coital test the next morning. The study was conducted on twenty seven women volunteers at two centers. The volunteers were examined within 12 h of coitus. The post coital test showed immobile spermatozoa in vaginal and endocervical aspirates. This pilot study clearly showed that CONSAP cream prepared from Sapindus Mukorossi, when used properly in indicated quantity can act as contraceptive without side effect.

 

Keywords: Sapindus Mukorossi, consap, contraceptive, vaginal cream

 

Cite this Article

Bhosale Vivek V, Ashim Ghatak. Clinical evaluation of vaginal contraceptive cream of sapindus mukorossi, CONSAP: a pilot study. Trends in Drug Delivery. 2015; 2(3): 22–24p.

Downloads

Published

2019-02-21

Issue

Vol. 2 No. 3 (2015)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.